АТОПИЧЕСКИЙ ДЕРМАТИТ: НОВОЕ В ЛЕЧЕНИИ
https://doi.org/10.15690/vsp.v12i5.802
Аннотация
Список литературы
1. Saavedra J., Boguniewicz M., Chamlin S., Lake A., Nedorost S., Czerkies L., Patel V., Botteman M., Horodniceanu E. Patterns of clinical management of atopic dermatitis in infants and toddlers: A survey of three physician specialities in the United States. J. Pediatr. 2013; 14: 168–171.
2. Kapoor R., Menon C., Hoffstad O., Bilker W., Leclerc P., Margolis D. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J. Am. Acad. Dermatol. 2008; 9: 68–73.
3. Leung D., Nicklas R., Li J., Bernstein I., Blessing-Moore J., Boguniewicz M., Chapman J., Khan D., Lang D., Lee R., Portnoy J., Schuller D., Spector S., Tilles S. Disease management of atopic derma titis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann. Allergy Asthma Immunol. 2004; 9 (Suppl. 2): 1–21.
4. Macharadze D.Sh. Atopicheskiy Dermatit: Sovremennye Metody Diagnostiki i Terapii. Uchebno-Metodicheskoe Posobie [Atopic Dermatitis: Modern Methods of Diagnosis and Therapy. A Teaching Manual]. Moscow, RPK “Liniya-Print” Publ., 2011. 75 p.
5. Suarez-Farinas M., Dhingra N., Gittler J., Shemer A., Cardinale I., de Guzman Strong K., Krueger J., Guttman-Yassky E. Intrinsic atopic dermatitis shows similar Th2 and higher Th17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 2013; 132: 361–370.
6. Segal A., Ellis А., Kim H. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy Asthma Clin. Immunol. 2013; 9 (1): 24–29.
7. Fleischer A., Boguniewicz M. An approach to pruritus in atopic dermatitis: A critical systematic review of the tacrolimus ointment literature. J. Drugs Dermatol. 2010; 9: 488–498.
8. Meingassner J., Aschauer H., Stuetz A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroidpretreated skin. Exp. Dermatol. 2005; 14: 752–757.
9. McCollum A., Paik A., Eichenfield L. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr. Dermatol. 2010; 9: 425–436.
10. Svensson A., Chambers C., Ganemo A., Mitchell S. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr. Med. Res. Opin. 2011; 12: 1385–1406.
11. Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U. K. National Health Service) perspective. Brit. J. Dermatol. 2011; 164: 387–395.
12. Tennis P., Gelfand J., Rothman K. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Brit. J. Dermatol. 2011; 165: 465–473.
13. Miyagaki T., Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J. Dermatol. Sci. 2011; 64: 1–6.
14. Siegfried E., Jaworski J., Hebert A. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am. J. Clin. Dermatol. 2013; 14: 163–178.
15. Mandelin J., Remitz A., Reitamo S. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. Arch. Dermatol. 2010; 146: 10.
Рецензия
Для цитирования:
Мачарадзе Д.Ш. АТОПИЧЕСКИЙ ДЕРМАТИТ: НОВОЕ В ЛЕЧЕНИИ. Вопросы современной педиатрии. 2013;12(5):80-85. https://doi.org/10.15690/vsp.v12i5.802
For citation:
Macharadze D.S. ATOPIC DERMATITIS: NEW ASPECTS OF TREATMENT. Current Pediatrics. 2013;12(5):80-85. (In Russ.) https://doi.org/10.15690/vsp.v12i5.802